Find 60+ employers at Clark County Job Fair
DAYTON, Ohio (WDTN) — Looking for a new job? If you head over to Clark County, you could find your next opportunity.
From 1:30 to 4:30 p.m. on April 15, individuals interested in finding a new job are encouraged to visit Hollenbeck-Bayley Creative Arts and Conference Center in Springfield.
Free and discounted food for Tax Day 2025
Over 60 employers and recruiters will be at the event looking for interested applicants.
Job opportunities will be available in customer and food services, education, health care, logistics, manufacturing and public service.
Attendees are encouraged bring their résumé, while dressing to impress.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Hawkins, Inc. to Participate in CJS Securities 25th Annual New Ideas Summer Conference
ROSEVILLE, Minn, June 11, 2025 (GLOBE NEWSWIRE) -- – Hawkins, Inc. (Nasdaq: HWKN), a leading water treatment and specialty ingredients company, today announced that it will participate in the CJS Securities 25th Annual New Ideas Summer Conference on July 10, 2025. The conference will be held at the Metropolis Country Club in White Plains, NY. The conference will be attended by a group of targeted institutional investors, where each company in attendance will have a presentation slot and will be available for one-on-one meetings. For more information about this conference or to schedule a meeting with Hawkins management, please contact the event coordinators or Hawkins Investor Relations at ir@ About Hawkins, Inc. Hawkins, Inc. was founded in 1938 and is a leading water treatment and specialty ingredients company that formulates, manufactures, distributes and blends products for its Water Treatment, Food & Health Sciences and Industrial Solutions customers. Headquartered in Roseville, Minnesota, the Company has 63 facilities in 28 states and creates value for its customers through superb customer service and support, quality products and personalized applications. Hawkins, Inc. generated $974 million of revenue in fiscal 2025 and has approximately 1,100 employees. For more information, including registering to receive email alerts, please visit CONTACT: Contact: Jeffrey P. Oldenkamp Executive Vice President and Chief Financial Officer 612/331-6910 ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Moleculin Participates in Virtual Investor 'What This Means' Segment
Globally recognized Oncology Key Opinion Leader, Brian Andrew Van Tine, MD, PhD, discusses the positive topline results from the U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) Watch the 'What This Means" segment here HOUSTON, June 11, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it participated in a Virtual Investor 'What This Means' segment. For the segment, Brian Andrew Van Tine, MD, PhD, Professor of Medicine, Washington University School of Medicine, discussed the Company's recently announced positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases ('STS lung mets') (MB-107). The MB-107 trial was a multi-center, open-label, single-arm monotherapy study that in Phase 1B determined the Maximum Tolerable Dose and Recommended Phase 2 Dose ('MTD', 'RP2D' respectively) and safety of Annamycin and in Phase 2 explored the efficacy of Annamycin as a single agent for the treatment of subjects with STS lung mets for which chemotherapy was considered appropriate. For more information about the MB-107 trial visit and reference identifier NCT04887298. The Virtual Investor 'What This Means' segment featuring Moleculin is now available here. About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit and connect on X, LinkedIn and Facebook. Forward-Looking StatementsSome of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the release of the initial data on the first 45 subjects in the trial and the Company's ability to reconcile the US and EU protocols with the FDA and EMA, respectively. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company's ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. 'Risk Factors' in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775MBRX@
Yahoo
20 minutes ago
- Yahoo
CompoSecure Announces CFO Retirement; Reaffirms Previously Issued Full Year 2025 Guidance
CompoSecure announces that Tim Fitzsimmons, its Chief Financial Officer, will retire from his position once a successor has been named and assumes the role, which is anticipated to occur in the second half of 2025, but no later than January 1, 2026. A comprehensive search will be launched for a CFO successor; Mr. Fitzsimmons will serve as a consultant commencing on his retirement date and through January 1, 2027 to ensure a smooth transition. CompoSecure reaffirms its previously issued full year 2025 guidance, which calls for mid-single digit growth in both Consolidated Net Sales and Pro Forma Adjusted EBITDA. SOMERSET, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- CompoSecure, Inc. (Nasdaq: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced that after more than 13 years of service, its Chief Financial Officer, Tim Fitzsimmons will retire once a successor has been named and assumes the role, which is anticipated to occur in the second half of 2025, but no later than January 1, 2026. Mr. Fitzsimmons will then serve as a consultant to CompoSecure through January 1, 2027 to ensure a smooth transition with his successor. Jon Wilk, President and CEO of CompoSecure, commented: 'When Tim approached me about his desire to retire, it gave me the opportunity to reflect on his significant contributions and impact on CompoSecure. He's played a central role supporting critical corporate transactions including our transition from private to public, the sale of a majority interest in CompoSecure and recent spin-off. He has built and maintained an outstanding lending group that has led to multiple debt financings to support our growth over the last ten years. Since I joined the company in 2016, Tim and I have worked closely to demonstrate the value a metal card can provide to our customers across the globe. As we seek a successor, I look forward to continuing to work alongside him in the coming months to further our financial discipline and accelerate the work we've started with the CompoSecure Operating System. Tim is leaving us in a strong position, and we are fully committed to a smooth and thoughtful transition that builds on this solid foundation.' Tim Fitzsimmons, Chief Financial Officer, said: 'Serving as CFO of CompoSecure for the past 13 years has been the most rewarding chapter of my professional career. I am deeply grateful to our founders John Herslow, Michele Logan, and Lou DaSilva for the opportunity to contribute as a member of the Senior Leadership Team, and for the strong, collaborative partnership I've shared with our current leadership. It has been a true privilege to lead the Finance and IT teams and to work with so many talented colleagues across the business throughout the years. I take great pride in the incredible journey we've shared—transforming CompoSecure from a family-owned business into a publicly traded company. Deciding to retire was a difficult choice rooted in family priorities, and it wasn't an easy one. As I begin this next phase, I remain fully committed to working closely with my successor to ensure a seamless handover and I'm focused on delivering strong outcomes for investors as we progress. Even as I step away from the role, I'll continue to cheer CompoSecure on—as a dedicated supporter and proud shareholder." Dave Cote, CompoSecure's Executive Chairman, further added: 'I am thankful for the lasting impact Tim has made on CompoSecure. His leadership has been central to building the foundation of our business today. The progress we've made as a company is in no small part due to his commitment and dedication through the years. I am confident that his impact will be felt well into the future.' CompoSecure Reaffirms Full Year 2025 Guidance CompoSecure is reaffirming its previously issued full year 2025 guidance, which calls for mid-single digit growth in both Consolidated Net Sales and Pro Forma Adjusted EBITDA. As mentioned previously, this guidance includes payment of the Resolute Holdings management fee, on a pro forma basis, in 2024 and 2025. About CompoSecure Founded in 2000, CompoSecure (Nasdaq: CMPO) is a technology partner to market leaders, fintechs and consumers enabling trust for millions of people around the globe. The company combines elegance, simplicity and security to deliver exceptional experiences and peace of mind in the physical and digital world. CompoSecure's innovative payment card technology and metal cards with Arculus security and authentication capabilities deliver unique, premium branded experiences, enable people to access and use their financial and digital assets, and ensure trust at the point of a transaction. For more information, please visit and Forward-Looking Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of management. Although CompoSecure believes that its plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, CompoSecure cannot assure you that it will achieve or realize these plans, intentions, or expectations. Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Generally, statements that are not historical facts, including statements concerning CompoSecure's planned CFO transition, guidance for fiscal year 2025, possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. In some instances, these statements may be preceded by, followed by, or include the words 'believes,' 'estimates,' 'expects,' 'projects,' 'forecasts,' 'may,' 'will,' 'should,' 'seeks,' 'plans,' 'scheduled,' 'anticipates' or 'intends' or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements which speak only as of the date hereof. You should understand that the following important factors, among others, could affect CompoSecure's future results and could cause those results or other outcomes to differ materially from those expressed or implied in CompoSecure's forward-looking statements: the ability of CompoSecure to grow and manage growth profitably, maintain relationships with customers, compete within its industry, retain its key employees and complete the management transition described in this press release on the timeline anticipated or at all; the possibility that CompoSecure may be adversely impacted by other global economic, business, competitive and/or other factors, including tariffs; the outcome of any legal proceedings that may be instituted against CompoSecure or others; future exchange and interest rates; changes in our accounting and/or financial presentation; and other risks and uncertainties, including those under 'Risk Factors' in filings that have been made or will be made with the Securities and Exchange Commission. CompoSecure undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Corporate Contact Anthony PiniellaHead of Communications, CompoSecure(917) 208-7724apiniella@ Investor Relations Contact Sean Mansouri, CFAElevate IR(720) 330-2829CMPO@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
